目的:我们评估了日本类风湿关节炎患者使用生物和靶向合成抗风湿药物治疗的社会经济影响。
方法:我们回顾性分析了前瞻性观察性CorEvitasRA日本注册中心(2016年3月至2020年2月)的数据。患者被分为带薪和家庭工人,并进一步根据药物类别进行分类。我们评估了药物的持久性;治疗结果;医疗资源利用;和社会经济影响超过12个月,包括直接(药物和医疗保健资源利用)和间接(生产力损失)成本。
结果:总体而言,已确认187名带薪家庭工人和114名家庭工人。超过12个月,药物持久性很高,治疗结果改善,两组的门诊量均减少。治疗开始后,直接成本增加,而两组的间接成本(生产率损失)均有所下降。未经调整的社会经济影响(日元[JPY])在所有有薪(范围:29,700-151,700)和家庭(范围:-28,700-83,000)工人中增加了。每月社会经济影响的调整后变化为带薪工人29,700-138,900日元,家庭工人为28,000-92,800日元。
结论:在这项针对日本类风湿性关节炎患者的研究中,患者群体和药物类别的社会经济负担增加.间接(生产率损失)成本的减少部分抵消了直接成本的增加。
OBJECTIVE: We evaluate the socioeconomic impact of treatment with biological and targeted synthetic disease-modifying antirheumatic drugs in Japanese patients with rheumatoid arthritis.
METHODS: We analysed data retrospectively from the prospective observational CorEvitas RA Japan Registry (March 2016-February 2020). Patients were categorised into paid workers (PWs) and home workers (HWs) and further based on drug classes. We assessed medication persistence, treatment outcomes, health care resource utilisation, and socioeconomic impact over 12 months, including direct (drugs and health care resource utilisation) and indirect (loss of productivity) costs.
RESULTS: Overall, 187 PWs and 114 HWs were identified. Over 12 months, medication persistence was high, treatment outcomes improved, and outpatient visits reduced in both groups. Following treatment initiation, direct costs increased, whereas indirect (loss of productivity) costs decreased in both groups. The unadjusted socioeconomic impact [Japanese yen (JPY)] increased across all drug classes in PWs (range: 29,700-151,700) and HWs (range: -28,700 to 83,000). Adjusted change in monthly socioeconomic impact was JPY 29,700-138,900 for PWs and JPY -28,000 to 92,800 for HWs.
CONCLUSIONS: In this study of Japanese patients with rheumatoid arthritis, the socioeconomic burden increased across patient groups and drug classes. The decrease in indirect (loss of productivity) costs partially offset the increase in direct costs.